Author:
Kuang Lei,Zhang Jingbo,Li Yanyu,Wang Qing,Liu Jianwei,Zhang Bei
Abstract
Abstract
Background
Aberrant DNA methylation is a vital molecular alteration commonly detected in type I endometrial cancers (EC), and tet methylcytosine dioxygenase 2 (TET2) and 5-hydroxymethylcytosine (5hmC) play significant roles in DNA demethylation. However, little is known about the function and correlation of TET2 and 5hmC co-expressed in EC. This study intended to investigate the clinical significance of TET2 and 5hmC in EC.
Methods
The levels of TET2 and 5hmC were detected in 326 endometrial tissues by immumohistochemistry, and the correlation of their level was detected by Pearson analysis. The association between the levels of TET2 and 5hmC and clinicopathologic characteristics was analyzed. Prognostic value of TET2 and 5hmC was explored by Kaplan–Meier analysis. The Cox proportional hazard regression model was used for univariate and multivariate analyses.
Results
Based on the analysis results, TET2 protein level was positively correlated with 5hmC level in EC tissues (r = 0.801, P < 0.001). TET2+5hmC+ (high TET2 and high 5hmC) association was significantly associated with well differentiation, myometrial invasion, negative lymph node metastasis, and tumor stage in EC. Association of TET2 and 5hmC was confirmed as a prognostic factor (HR = 2.843, 95%CI = 1.226–3.605, P = 0.007) for EC patients, and EC patients with TET2−5hmC− level had poor overall survival.
Conclusions
In summary, the association of TET2 and 5hmC was downregulated in EC tissues, and may be a potential poor prognostic indicator for EC patients. Combined detection of TET2 and 5hmC may be valuable for the diagnosis and prognosis of EC.
Funder
Xuzhou introduced clinical medical expert team project
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy
the Jiangsu Science and Technology planning project
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Ha Thout L, Wang Y, Wang Q, Vergalasova I, Lee LJ. A multi-institutional analysis of adjuvant chemotherapy and radiation sequence in women with Stage IIIC endometrial cancer. Int J Radiat Oncol Biol Phys. 2021;110:1423–31.
2. Joannie LT, Jacques F, Freddie B, Ahmedin J. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:4.
3. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncology. 2012;13:e353–61.
4. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer Lacent. 2016;387:1094–108.
5. JIn W, Wang L, Liu Y, Liu A. Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer. Chin J Obstet Gynecol. 2018;053:823–30.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献